Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.
Department of Medicine, Dermatology, and Neurology, Division of Gastroenterology and Rheumatology, University of Leipzig, Germany.
Johannes
J
Wiegand
Konrad
K
Neumann
Stephan
S
Böhm
Viola
V
Weich
Gerlinde
G
Teuber
Hartwig
H
Klinker
Bernd
B
Möller
Jens
J
Rasenack
Holger
H
Hinrichsen
Tilman
T
Gerlach
Ulrich
U
Spengler
Peter
P
Buggisch
Christoph
C
Sarrazin
Thomas
T
Berg
D000998:Antiviral Agents / Q000008:administration & dosage; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage; D018570:Risk Assessment; D019562:Viral Load; D014766:Viremia
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b